购物车
全部删除
您的购物车当前为空
MET Transcription-IN-1 (Compound C3) 是一种口服活性的MET转录抑制剂,能够高效结合并稳定MET启动子区的G-四链体,从而抑制c-Met的表达,并克服特定c-Met突变导致的耐药性。此化合物能够抑制肿瘤细胞的增殖、迁移和侵袭,并诱导细胞周期阻滞及凋亡 (apoptosis),具有抗肿瘤活性,适用于非小细胞肺癌等肿瘤研究。

MET Transcription-IN-1 (Compound C3) 是一种口服活性的MET转录抑制剂,能够高效结合并稳定MET启动子区的G-四链体,从而抑制c-Met的表达,并克服特定c-Met突变导致的耐药性。此化合物能够抑制肿瘤细胞的增殖、迁移和侵袭,并诱导细胞周期阻滞及凋亡 (apoptosis),具有抗肿瘤活性,适用于非小细胞肺癌等肿瘤研究。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | 待询 | 10-14周 | |
| 50 mg | 待询 | 10-14周 |
MET Transcription-IN-1 相关产品
| 产品描述 | MET Transcription-IN-1 (Compound C3) is an orally active inhibitor of MET transcription that efficiently binds to and stabilizes the G-quadruplex in the MET promoter region, thereby inhibiting c-Met expression. It can overcome resistance caused by specific c-Met mutations and effectively inhibits tumor cell proliferation, migration, and invasion, inducing cell cycle arrest and apoptosis. This compound exhibits antitumor activity and is applicable in the study of tumors such as non-small cell lung cancer. |
| 分子量 | 392.41 |
| 分子式 | C24H16N4O2 |
| CAS No. | 3082125-66-1 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容